Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy.This was a randomized, pros...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4414350?pdf=render |
| _version_ | 1828937638741016576 |
|---|---|
| author | Cheryl A London Heather L Gardner Tamra Mathie Nicole Stingle Roberta Portela Michael L Pennell Craig A Clifford Mona P Rosenberg David M Vail Laurel E Williams Kim L Cronin Heather Wilson-Robles Antonella Borgatti Carolyn J Henry Dennis B Bailey Jennifer Locke Nicole C Northrup Martin Crawford-Jakubiak Virginia L Gill Mary K Klein David M Ruslander Doug H Thamm Brenda Phillips Gerald Post |
| author_facet | Cheryl A London Heather L Gardner Tamra Mathie Nicole Stingle Roberta Portela Michael L Pennell Craig A Clifford Mona P Rosenberg David M Vail Laurel E Williams Kim L Cronin Heather Wilson-Robles Antonella Borgatti Carolyn J Henry Dennis B Bailey Jennifer Locke Nicole C Northrup Martin Crawford-Jakubiak Virginia L Gill Mary K Klein David M Ruslander Doug H Thamm Brenda Phillips Gerald Post |
| author_sort | Cheryl A London |
| collection | DOAJ |
| description | We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy.This was a randomized, prospective clinical trial in which dogs with OSA free of gross metastatic disease (n = 126) received carboplatin chemotherapy (4 doses) following amputation. On study entry, dogs were randomized to receive piroxicam/cyclophosphamide with or without toceranib (n = 63 each) after completing chemotherapy. Patient demographics were not significantly different between both groups. During or immediately following carboplatin chemotherapy, 32 dogs (n = 13 toceranib; n = 19 control) developed metastatic disease, and 13 dogs left the study due to other medical conditions or owner preference. Following carboplatin chemotherapy, 81 dogs (n = 46 toceranib; n = 35 control) received the metronomic treatment; 35 dogs (n = 20 toceranib; n = 15 control) developed metastatic disease during the maintenance therapy, and 26 dogs left the study due to other medical conditions or owner preference. Nine toceranib-treated and 11 control dogs completed the study without evidence of metastatic disease 1-year following amputation. Toceranib-treated dogs experienced more episodes of diarrhea, neutropenia and weight loss than control dogs, although these toxicities were low-grade and typically resolved with supportive care. More toceranib-treated dogs (n = 8) were removed from the study for therapy-associated adverse events compared to control dogs (n = 1). The median DFI for control and toceranib treated dogs was 215 and 233 days, respectively (p = 0.274); the median OS for control and toceranib treated dogs was 242 and 318 days, respectively (p = 0.08). The one year survival rate for control dogs was 35% compared to 38% for dogs receiving toceranib.The addition of toceranib to metronomic piroxicam/cyclophosphamide therapy following amputation and carboplatin chemotherapy did not improve median DFI, OS or the 1-year survival rate in dogs with OSA. |
| first_indexed | 2024-12-14T02:27:16Z |
| format | Article |
| id | doaj.art-a53bde96293544248c55b1e08df0a365 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T02:27:16Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a53bde96293544248c55b1e08df0a3652022-12-21T23:20:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012488910.1371/journal.pone.0124889Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.Cheryl A LondonHeather L GardnerTamra MathieNicole StingleRoberta PortelaMichael L PennellCraig A CliffordMona P RosenbergDavid M VailLaurel E WilliamsKim L CroninHeather Wilson-RoblesAntonella BorgattiCarolyn J HenryDennis B BaileyJennifer LockeNicole C NorthrupMartin Crawford-JakubiakVirginia L GillMary K KleinDavid M RuslanderDoug H ThammBrenda PhillipsGerald PostWe hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy.This was a randomized, prospective clinical trial in which dogs with OSA free of gross metastatic disease (n = 126) received carboplatin chemotherapy (4 doses) following amputation. On study entry, dogs were randomized to receive piroxicam/cyclophosphamide with or without toceranib (n = 63 each) after completing chemotherapy. Patient demographics were not significantly different between both groups. During or immediately following carboplatin chemotherapy, 32 dogs (n = 13 toceranib; n = 19 control) developed metastatic disease, and 13 dogs left the study due to other medical conditions or owner preference. Following carboplatin chemotherapy, 81 dogs (n = 46 toceranib; n = 35 control) received the metronomic treatment; 35 dogs (n = 20 toceranib; n = 15 control) developed metastatic disease during the maintenance therapy, and 26 dogs left the study due to other medical conditions or owner preference. Nine toceranib-treated and 11 control dogs completed the study without evidence of metastatic disease 1-year following amputation. Toceranib-treated dogs experienced more episodes of diarrhea, neutropenia and weight loss than control dogs, although these toxicities were low-grade and typically resolved with supportive care. More toceranib-treated dogs (n = 8) were removed from the study for therapy-associated adverse events compared to control dogs (n = 1). The median DFI for control and toceranib treated dogs was 215 and 233 days, respectively (p = 0.274); the median OS for control and toceranib treated dogs was 242 and 318 days, respectively (p = 0.08). The one year survival rate for control dogs was 35% compared to 38% for dogs receiving toceranib.The addition of toceranib to metronomic piroxicam/cyclophosphamide therapy following amputation and carboplatin chemotherapy did not improve median DFI, OS or the 1-year survival rate in dogs with OSA.http://europepmc.org/articles/PMC4414350?pdf=render |
| spellingShingle | Cheryl A London Heather L Gardner Tamra Mathie Nicole Stingle Roberta Portela Michael L Pennell Craig A Clifford Mona P Rosenberg David M Vail Laurel E Williams Kim L Cronin Heather Wilson-Robles Antonella Borgatti Carolyn J Henry Dennis B Bailey Jennifer Locke Nicole C Northrup Martin Crawford-Jakubiak Virginia L Gill Mary K Klein David M Ruslander Doug H Thamm Brenda Phillips Gerald Post Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS ONE |
| title | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. |
| title_full | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. |
| title_fullStr | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. |
| title_full_unstemmed | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. |
| title_short | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. |
| title_sort | impact of toceranib piroxicam cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy a multi institutional study |
| url | http://europepmc.org/articles/PMC4414350?pdf=render |
| work_keys_str_mv | AT cherylalondon impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT heatherlgardner impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT tamramathie impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT nicolestingle impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT robertaportela impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT michaellpennell impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT craigaclifford impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT monaprosenberg impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT davidmvail impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT laurelewilliams impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT kimlcronin impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT heatherwilsonrobles impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT antonellaborgatti impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT carolynjhenry impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT dennisbbailey impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT jenniferlocke impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT nicolecnorthrup impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT martincrawfordjakubiak impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT virginialgill impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT marykklein impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT davidmruslander impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT doughthamm impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT brendaphillips impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy AT geraldpost impactoftoceranibpiroxicamcyclophosphamidemaintenancetherapyonoutcomeofdogswithappendicularosteosarcomafollowingamputationandcarboplatinchemotherapyamultiinstitutionalstudy |